Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore

Richard D. Semba; Erin P. Ricketts; Shruti F. Mehta; Gregory D. Kirk; Carl Latkin; Noya Galai; David Vlahov

doi:10.1080/00952990601082696

Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore

Richard D. Semba, Erin P. Ricketts, Shruti F. Mehta, Gregory D. Kirk, Carl Latkin, Noya Galai, David Vlahov

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

Adherence and retention of female injection drug users (IDUs) in clinical trials are not well known and were evaluated among 458 female IDUs in a clinical trial in Baltimore. Of all, 62.9% were adherent to visits (attended ≥ 80% of visits). Of women with ≥ 1 visit after enrollment, 76% were adherent to treatment (took ≥ 80% of pills); 27.7% were lost to follow-up (missed ≥ 3 consecutive visits). Women nonadherent to visits were younger and less likely to be on methadone. Women lost to follow-up were younger, more often white, not on methadone, and injecting drugs daily. Fair-moderate adherence to visits and treatment occurs among female IDUs in a clinical trial.

Original language	English (US)
Pages (from-to)	71-80
Number of pages	10
Journal	American Journal of Drug and Alcohol Abuse
Volume	33
Issue number	1
DOIs	https://doi.org/10.1080/00952990601082696
State	Published - Jan 2007

Keywords

Adherence
Clinical trial
HCV
HIV
Injection drug user
Minority

ASJC Scopus subject areas

Medicine (miscellaneous)
Clinical Psychology
Psychiatry and Mental health

Access to Document

10.1080/00952990601082696

Cite this

@article{a8d6495605564cfb936bdbfae282f34b,

title = "Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore",

abstract = "Adherence and retention of female injection drug users (IDUs) in clinical trials are not well known and were evaluated among 458 female IDUs in a clinical trial in Baltimore. Of all, 62.9% were adherent to visits (attended ≥ 80% of visits). Of women with ≥ 1 visit after enrollment, 76% were adherent to treatment (took ≥ 80% of pills); 27.7% were lost to follow-up (missed ≥ 3 consecutive visits). Women nonadherent to visits were younger and less likely to be on methadone. Women lost to follow-up were younger, more often white, not on methadone, and injecting drugs daily. Fair-moderate adherence to visits and treatment occurs among female IDUs in a clinical trial.",

keywords = "Adherence, Clinical trial, HCV, HIV, Injection drug user, Minority",

author = "Semba, {Richard D.} and Ricketts, {Erin P.} and Mehta, {Shruti F.} and Kirk, {Gregory D.} and Carl Latkin and Noya Galai and David Vlahov",

note = "Funding Information: This study was supported by the National Institute on Nursing Research (R01 NR009478) and the National Institute on Drug Abuse (R01 DA15022).",

year = "2007",

month = jan,

doi = "10.1080/00952990601082696",

language = "English (US)",

volume = "33",

pages = "71--80",

journal = "American Journal of Drug and Alcohol Abuse",

issn = "0095-2990",

publisher = "Informa Healthcare",

number = "1",

}

TY - JOUR

T1 - Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore

AU - Semba, Richard D.

AU - Ricketts, Erin P.

AU - Mehta, Shruti F.

AU - Kirk, Gregory D.

AU - Latkin, Carl

AU - Galai, Noya

AU - Vlahov, David

N1 - Funding Information: This study was supported by the National Institute on Nursing Research (R01 NR009478) and the National Institute on Drug Abuse (R01 DA15022).

PY - 2007/1

Y1 - 2007/1

N2 - Adherence and retention of female injection drug users (IDUs) in clinical trials are not well known and were evaluated among 458 female IDUs in a clinical trial in Baltimore. Of all, 62.9% were adherent to visits (attended ≥ 80% of visits). Of women with ≥ 1 visit after enrollment, 76% were adherent to treatment (took ≥ 80% of pills); 27.7% were lost to follow-up (missed ≥ 3 consecutive visits). Women nonadherent to visits were younger and less likely to be on methadone. Women lost to follow-up were younger, more often white, not on methadone, and injecting drugs daily. Fair-moderate adherence to visits and treatment occurs among female IDUs in a clinical trial.

AB - Adherence and retention of female injection drug users (IDUs) in clinical trials are not well known and were evaluated among 458 female IDUs in a clinical trial in Baltimore. Of all, 62.9% were adherent to visits (attended ≥ 80% of visits). Of women with ≥ 1 visit after enrollment, 76% were adherent to treatment (took ≥ 80% of pills); 27.7% were lost to follow-up (missed ≥ 3 consecutive visits). Women nonadherent to visits were younger and less likely to be on methadone. Women lost to follow-up were younger, more often white, not on methadone, and injecting drugs daily. Fair-moderate adherence to visits and treatment occurs among female IDUs in a clinical trial.

KW - Adherence

KW - Clinical trial

KW - HCV

KW - HIV

KW - Injection drug user

KW - Minority

UR - http://www.scopus.com/inward/record.url?scp=33947231783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33947231783&partnerID=8YFLogxK

U2 - 10.1080/00952990601082696

DO - 10.1080/00952990601082696

M3 - Article

C2 - 17366247

AN - SCOPUS:33947231783

SN - 0095-2990

VL - 33

SP - 71

EP - 80

JO - American Journal of Drug and Alcohol Abuse

JF - American Journal of Drug and Alcohol Abuse

IS - 1

ER -

Adherence and retention of female injection drug users in a phase III clinical trial in inner city Baltimore

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this